© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Diana Bitner, MD, MSCP, FACOG
Articles
Final Thoughts on Vasomotor Symptoms and NK Receptor Antagonism
December 17, 2025
Panelists discuss how advancing NK receptor research is reshaping menopause care, emphasizing education, innovation, and patient empowerment for lasting impact.
Practical Strategies for Integrating NK Receptor Antagonism for Vasomotor Symptoms Into Primary Care
December 17, 2025
Panelists discuss how structured monitoring and interdisciplinary collaboration enable safe, effective integration of NK-targeted therapies into primary care.
Positioning NK Receptor Antagonism in the Vasomotor Symptoms Treatment Landscape
December 10, 2025
Panelists discuss how NK receptor antagonists can be strategically positioned as core nonhormonal options within the broader VMS treatment landscape.
Beyond Vasomotor Symptoms: The Potential Role of NK Receptor Antagonism in Mood and Sleep
December 10, 2025
Panelists discuss how NK receptor antagonism may improve mood and sleep quality, linking thermoregulation with broader emotional and cognitive health benefits.
Exploring the Broader Therapeutic Potential of NK1 Receptor Antagonists Beyond Vasomotor Symptoms
December 03, 2025
Panelists discuss how NK1 receptor antagonists show promise beyond VMS, suggesting wider therapeutic potential across neurological and systemic conditions.
Evaluating the Rapid Onset of Vasomotor Symptom Improvement and Safety Profiles of NK Receptor Antagonists
December 03, 2025
Panelists discuss how NK receptor antagonists deliver fast symptom relief with strong safety profiles, improving adherence and clinical confidence in their use.
Efficacy and Safety of Elinzanetant in Vasomotor Symptoms in Women With Breast Cancer Receiving Endocrine Therapy
November 26, 2025
Panelists discuss how elinzanetant offers a safe, effective nonhormonal option for managing VMS in women receiving endocrine therapy for breast cancer.
Efficacy and Safety of Elinzanetant in Vasomotor Symptoms in Menopause
November 26, 2025
Panelists discuss how elinzanetant demonstrates strong efficacy and safety across trials, reinforcing neurokinin modulation as a viable core treatment for VMS.
Dual NK3/NK1 Receptor Antagonism for Vasomotor Symptoms
November 19, 2025
Panelists discuss how dual NK3/NK1 receptor antagonism may expand therapeutic benefits by targeting multiple neural pathways involved in VMS and mood regulation.
Managing Vasomotor Symptoms With NK3 Receptor Antagonism
November 19, 2025
Panelists discuss how NK3 receptor antagonism through fezolinetant offers effective, rapid relief from VMS with a strong safety profile and nonhormonal benefits.